Merck plans $2.5 bln annual cost reductions, 8,500 job cuts
Oct 1 (Reuters) - U.S. drugmaker Merck & Co, taking a cue from other drugmakers that have slashed research spending to prop up earnings, on Tuesday said it plans to cut annual operating costs by about $2.5 billion by the end of 2015 and eliminate 8,500 jobs.
By slimming itself down, Merck said it would be able to bolster its pipeline of experimental drugs, many of which have failed to win regulatory approval or suffered other setbacks in the past few years.
- Russia criticizes EU sanctions, raps U.S. over Ukraine role |
- Israel says ready to extend short Gaza truce; many bodies pulled from rubble |
- First Ebola victim in Sierra Leone capital on the run
- Amazon's far-reaching ambitions, lack of profits, unnerve investors |
- Apple iPhones allow extraction of deep personal data, researcher finds